Virios Therapeutics, Inc. (NASDAQ:VIRI – Get Rating) saw a large decline in short interest in May. As of May 15th, there was short interest totalling 327,500 shares, a decline of 68.8% from the April 30th total of 1,050,000 shares. Based on an average trading volume of 2,790,000 shares, the days-to-cover ratio is presently 0.1 days.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp acquired a new stake in Virios Therapeutics in the 2nd quarter valued at about $45,000. Envestnet Asset Management Inc. increased its holdings in shares of Virios Therapeutics by 10.5% during the 1st quarter. Envestnet Asset Management Inc. now owns 120,663 shares of the company’s stock worth $44,000 after buying an additional 11,467 shares during the last quarter. UBS Group AG increased its holdings in shares of Virios Therapeutics by 528.3% during the 1st quarter. UBS Group AG now owns 14,137 shares of the company’s stock worth $63,000 after buying an additional 11,887 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Virios Therapeutics by 33.3% during the 4th quarter. Renaissance Technologies LLC now owns 235,400 shares of the company’s stock worth $56,000 after buying an additional 58,800 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Virios Therapeutics by 63.4% during the 1st quarter. Vanguard Group Inc. now owns 241,666 shares of the company’s stock worth $1,082,000 after buying an additional 93,800 shares during the last quarter. Hedge funds and other institutional investors own 13.63% of the company’s stock.
Virios Therapeutics Price Performance
NASDAQ VIRI traded up $0.14 on Friday, hitting $1.35. The company had a trading volume of 315,171 shares, compared to its average volume of 1,956,922. The company has a market capitalization of $11.24 million, a PE ratio of -1.47 and a beta of 2.05. The company’s fifty day moving average price is $0.72 and its 200-day moving average price is $0.45. Virios Therapeutics has a 12-month low of $0.22 and a 12-month high of $9.11.
Virios Therapeutics Company Profile
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
- Get a free copy of the StockNews.com research report on Virios Therapeutics (VIRI)
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.